Furthermore, CD22-TTC (BAY 1862864) has been investigated in a Phase 1 study in patients with CD22-positive relapsed/refractory B-cell non-Hodgkin lymphoma (23). Here, CD22 is linked to B-cell non-Hodgkin lymphoma.